Mar 31, 2026 06:59AM
Mar 31, 2026 06:59AM
Feb 24, 2026 07:05AM
Jan 12, 2026 07:00AM
Dec 21, 2025 08:00PM
Dec 3, 2025 05:05PM
Dec 3, 2025 05:05PM The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
Oct 30, 2025 07:05AM
Oct 20, 2025 05:12AM
Jul 31, 2025 07:05AM
Jul 30, 2025 08:34AM
Jul 29, 2025 07:07AM
Jul 28, 2025 07:19PM
Jul 1, 2025 07:03AM Apellis Pharmaceuticals (APLS) to Receive up to $300M from Royalty Purchase Agreement with Sobi
Jul 1, 2025 07:00AM
Jun 6, 2025 09:16AM
Jun 6, 2025 09:15AM
May 21, 2025 04:54PM
May 7, 2025 07:00AM
Apr 1, 2025 07:01AM
Apr 1, 2025 07:00AM Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
Feb 28, 2025 07:05AM
Feb 20, 2025 02:00AM
Feb 13, 2025 06:02AM
Jan 13, 2025 09:07AM
Jan 13, 2025 09:00AM
Jan 7, 2025 04:05PM
Dec 6, 2024 04:05PM Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 19, 2024 07:48AM
Nov 5, 2024 07:05AM
Oct 26, 2024 02:00PM
Aug 8, 2024 08:05AM
Aug 8, 2024 07:29AM
Aug 8, 2024 07:01AM
Aug 8, 2024 07:00AM Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
Aug 1, 2024 08:00AM
Aug 1, 2024 07:05AM
May 24, 2024 10:00AM
May 14, 2024 08:02AM
May 14, 2024 08:00AM
May 7, 2024 07:05AM
Feb 27, 2024 07:05AM Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 5, 2024 04:36AM
Nov 9, 2023 06:28AM
Nov 6, 2023 12:13PM
Nov 6, 2023 09:59AM
Nov 4, 2023 01:37PM
Nov 2, 2023 09:00PM
Nov 1, 2023 04:03PM Mizuho Securities Starts Apellis Pharmaceuticals (APLS) at Neutral, 'Current Line of Sight Unclear'
Nov 1, 2023 07:05AM

322,218 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All